

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000

L1 30772 SEA SUPPLEMENT
L2 30 SEA L1 AND NITRIC OXIDE PRODUCTION
L3 0 SEA L2 AND SAPONINS
L4 0 SEA L2 AND GENSING
L5 25 SEA L2 AND L(W)ARGININE
L6 1 SEA L2 AND N(W)ACETYL(W)CYSTEINE
DISPLAY BROWSE
L7 1 SEA L2 AND FOLIC ACID
DISPLAY BROWSE

FILE 'CAPLUS' ENTERED AT 17:20:40 ON 03 APR 2000

L8 1039 SEA NITRIC OXIDE PRODUCTION
L9 2 SEA L8 AND FOLIC ACID
DISPLAY BROWSE

L1 30772 SEA SUPPLEMENT
L2 30 SEA L1 AND NITRIC OXIDE PRODUCTION
L3 0 SEA L2 AND SAPONINS
L4 0 SEA L2 AND GENSING
L5 25 SEA L2 AND L(W) ARGININE
L6 1 SEA L2 AND N(W) ACETYL(W) CYSTEINE
DISPLAY BROWSE
L7 1 SEA L2 AND FOLIC ACID
DISPLAY BROWSE

EXF 514/45; 514/565
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1, kwic

L7 ANSWER 1 OF 1 USPATFULL

SUMM Endogenous **nitric oxide production** can
also increase blood flow by reducing the number of blood elements
adhering to the lumen of the vessel. In. . .
SUMM Examples of vitamins suitable for incorporation into the medicament of
the invention include Vitamin A, Vitamin D, Vitamin K, **folic**
acid, thiamin, riboflavin, Vitamin B.sub.6, Vitamin B.sub.12,
niacin, biotin and panthotenic acid in pharmaceutically acceptable
form.
SUMM The medicament or formulation is primarily intended for use as a
dietary
supplement. In such a case, the amount of energy supplied by it
should not be too excessive, in order not to unnecessarily suppress the
patients appetite. The **supplement** should conveniently comprise
energy sources in an amount supplying from 600 to 1500 Kcal/day. The
contribution of the nitrogen source, . . .

| | | |
|--|------------|-------|
| DETD | . . . diet | 0.10 |
| Zinc | mg/kg diet | 12.00 |
| The vitamin mixture comprises per kg diet: | | |
| A.sup.(1) | 4000.00 | IU |
| D.sup.(2) | 1000.00 | IU |
| E.sup.(3) | 30.00 | IU |
| K.sub.1 | 50.00 | .mu.g |
| Choline | 1000.00 | mg |
| Folic acid | 1.00 | mg |
| Niacin | 20.00 | mg |
| Pantothenate (calcium) | 8.00 | mg |
| Riboflavin | 3.00 | mg |
| Thiamin | 4.00 | mg |
| Vitamin B.sub.6 | 6.00 | mg |
| Vitamin B.sub.12 | 50.00 | .mu.g |

.sup.(1) Vitamin A: . . .
ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:end

=> display his

ENTER (BRIEF) OR FULL:fi8ull

'FI8ULL' IS NOT VALID HERE
If you enter "BRIEF", you will see a short review of your session
history. If you enter "FULL", you will see a complete review of your
session history.
ENTER (BRIEF) OR FULL:display his

'DISPLAY HIS' IS NOT VALID HERE
If you enter "BRIEF", you will see a short review of your session
history. If you enter "FULL", you will see a complete review of your
session history.
ENTER (BRIEF) OR FULL:full

ENTER (L1-), L#, OR ?:L1-

(FILE 'HOME' ENTERED AT 17:09:59 ON 03 APR 2000)

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000

CA INDEXING IS CURRENT THROUGH 28 Mar 2000 (20000328/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Mar 2000 (20000328/PD)
REVISED CLASS FIELDS (/L) LAST RELOADED: Oct 1999
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: NOV 1999

>>> Page images are available for patents from 1/1/96. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s supplement

L1 30772 SUPPLEMENT

=> s L1 and nitric oxide production

49710 NITRIC
348134 OXIDE
532819 PRODUCTION
207 NITRIC OXIDE PRODUCTION
(NITRIC(W)OXIDE(W)PRODUCTION)

L2 30 L1 AND NITRIC OXIDE PRODUCTION

=> s L2 and saponins

1085 SAPONINS
L3 0 L2 AND SAPONINS

=> s L2 and gensing

2 GENSING
L4 0 L2 AND GENSING

=> s L2 and l(w)arginine

611177 L
19592 ARGININE
3493 L(W)ARGININE
L5 25 L2 AND L(W)ARGININE

=> s L2 and N(w)acetyl(w)cysteine

773027 N
66709 ACETYL
17143 CYSTEINE
398 N(W)ACETYL(W)CYSTEINE
L6 1 L2 AND N(W)ACETYL(W)CYSTEINE

=> display browse

ENTER (L6) OR L#:L6

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L6 ANSWER 1 OF 1 USPATFULL
AN 1999:43208 USPATFULL
TI Enhancement of vascular function by modulation of endogenous
nitric oxide production or activity
IN Cooke, John P., Palo Alto, CA, United States
Dzau, Victor J., Los Altos Hills, CA, United States
Gibbons, Gary H., Palo Alto, CA, United States
PA The Board of Trustees of the Leland Stanford Junior University,
Stanford, CA, United States (U.S. corporation)
PI US 5891459 19990406
AI US 1995-556035 19951109 (8)
RLI Continuation-in-part of Ser. No. US 1994-336159, filed on 8 Nov 1994,
now abandoned which is a continuation-in-part of Ser. No. US
1993-76312,
filed on 11 Jun 1993, now patented, Pat. No. US 5428070
DT Utility
LN.CNT 1730
INCL INCLM: 424/439.000
INCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000
NCL NCLM: 424/439.000
NCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000
IC [6]
ICM: A23L001-305
ICS: A61K009-00; A61K031-195
EXF 930/290; 530/358; 426/648; 426/656; 426/657; 514/310; 514/20; 514/557;
514/564; 514/565; 424/439; 424/441
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L6 ANSWER 1 OF 1 USPATFULL
AN 1999:43208 USPATFULL
TI Enhancement of vascular function by modulation of endogenous
nitric oxide production or activity
IN Cooke, John P., Palo Alto, CA, United States
Dzau, Victor J., Los Altos Hills, CA, United States
Gibbons, Gary H., Palo Alto, CA, United States
PA The Board of Trustees of the Leland Stanford Junior University,
Stanford, CA, United States (U.S. corporation)
PI US 5891459 19990406
AI US 1995-556035 19951109 (8)
RLI Continuation-in-part of Ser. No. US 1994-336159, filed on 8 Nov 1994,
now abandoned which is a continuation-in-part of Ser. No. US
1993-76312,
filed on 11 Jun 1993, now patented, Pat. No. US 5428070
DT Utility
LN.CNT 1730
INCL INCLM: 424/439.000
INCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000
NCL NCLM: 424/439.000
NCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000
IC [6]
ICM: A23L001-305
ICS: A61K009-00; A61K031-195
EXF 930/290; 530/358; 426/648; 426/656; 426/657; 514/310; 514/20; 514/557;
514/564; 514/565; 424/439; 424/441
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1, kwic

L6 ANSWER 1 OF 1 USPATFULL

TI Enhancement of vascular function by modulation of endogenous
nitric oxide production or activity

SUMM . . . combination with L-lysine, particularly further supplemented
 with GRAS substances which enhance the effectiveness of the active
 agents, as a dietary **supplement** will increase NO elaboration
 and thereby diminish the effects of atherogenesis. Other techniques to
 enhance NO or secondary messenger availability. . .

DRWD FIGS. 2A, 2B, and 2C are nephelometric scans of the effect of
 L-arginine
 diet **supplement** on platelet reactivity as evidenced by
 platelet aggregation initiated by adenosine diphosphate. (See Ex. 2) A)
 aggregation of platelets from. . .

DRWD FIG. 3 is a bar diagram comparing the effect of L-arginine diet
supplement on cell binding to aortic endothelium of
 hypercholesterolemic animals. (See Ex. 4)

DETD . . . amino acids, in combination, or as a precursor to L-arginine,
 e. g. a monomer or a polypeptide, as a dietary **supplement**. The
 amino acid(s) are administered as any physiologically acceptable salt,
 such as the hydrochloride salt, glutamate salt, etc. They can. . .

DETD . . . calcium (250-1000 mg per daily dose). Furthermore, agents
 known
 to protect NO from degradation, such as antioxidants (e.g. cysteine or
N-acetyl cysteine 200-1000 mg/d Vitamin C
 (250-2000 mg daily dose), (coenzyme Q 25-90 mg daily dose, glutathione
 50-250 mg daily dose), Vitamin. . . formulations of R and/or K, or R
 and/or K-containing peptides. Alternatively, one may include the active
 agent in a nutritional **supplement**, where other additives may
 include vitamins, amino acids, or the like, where the subject active
 agent will be at least. . .

DETD . . . candies, sugar substitutes, soft drinks, and the like. Of
 particular interest is the incorporation of R and/or K as a
supplement in a food, such as a health bar, e.g. granola, other
 grains, fruit bars, such as a date bar, fig. . .

DETD . . . studies, the extent of the thoracic aorta involved by lesions
 was examined. In hypercholesterolemic rabbits receiving vehicle (n=6)
 or
 L-arginine **supplement** (n=6), thoracic aortae (from left
 subclavian artery to diaphragm) were harvested after ten weeks of
 treatment, bisected longitudinally, and stained. . .

CLM What is claimed is:
 . . . of the vascular system of a human host by enhancing endothelial NO,
 said method comprising: administering orally as a dietary
supplement to said host in accordance with a predetermined
 regimen a prophylactic dose in an amount sufficient to enhance
 endogenous endothelial. . .
 . . . of the vascular system of a human host by enhancing endothelial NO,
 said method comprising: administering orally as a dietary
supplement to said host in accordance with a predetermined
 regimen a prophylactic dose in an amount sufficient to enhance
 endogenous endothelial. . .
 . . . of the vascular system of a human host by enhancing endothelial NO,
 said method comprising: administering orally as a dietary
supplement to said host in accordance with a predetermined
 regimen a prophylactic dose in an amount sufficient to enhance
 endogenous endothelial. . .

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:end

=> display his

ENTER (BRIEF) OR FULL:full

ENTER (L1-), L#, OR ?:L1-

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:sssptaul83jxs
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Feb 2 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 Expanded CAPlus Coverage of US, Japanese, WIPO,
EPO, and German patents
NEWS 3 Feb 1 Addition of Machine-Translated Abstracts to CAPlus
NEWS 4 Feb 2 STEREO BOND SEARCH PROBLEM FIXED WITH STN EXPRESS 5.0C
NEWS 5 Feb 14 Homology Searching for Nucleotide Sequences in DGENE
now available!
NEWS 6 Feb 16 BIOTECHNOBASE NOW ON STN
NEWS 7 Feb 22 New Database Producer Clusters Now Available on STN
NEWS 8 Feb 28 Structure Search Limits Increased in REGISTRY,
ZREGISTRY, and CASREACT
NEWS 9 Feb 28 Patent Information Now Searchable in CAOLD
NEWS 10 Mar 1 New IMSDIRECTORY Provides Pharma Company Details
NEWS 11 Mar 20 INPADOC: PRODUCER WARNING ABOUT DATA DELAYS
NEWS 12 Mar 22 NEW FEATURES IN INPADOC - RANGE SEARCHING AND NEW
SDI/UPDATE SEARCH FIELD

NEWS EXPRESS FREE UPGRADE 5.0C NOW AVAILABLE
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:09:59 ON 03 APR 2000

=> file uspatfull

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|---------------------|------------------|
| FULL ESTIMATED COST | 0.15 | 0.15 |

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Mar 2000 (20000328/PD)
FILE LAST UPDATED: 28 Mar 2000 (20000328/ED)
HIGHEST PATENT NUMBER: US6044489

(FILE 'HOME' ENTERED AT 17:09:59 ON 03 APR 2000)

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000

L1 30772 SEA SUPPLEMENT
L2 30 SEA L1 AND NITRIC OXIDE PRODUCTION
L3 0 SEA L2 AND SAPONINS
L4 0 SEA L2 AND GENSING
L5 25 SEA L2 AND L(W)ARGININE
L6 1 SEA L2 AND N(W)ACETYL(W)CYSTEINE
DISPLAY BROWSE

FILE HOME

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Mar 2000 (20000328/PD)

FILE LAST UPDATED: 28 Mar 2000 (20000328/ED)

HIGHEST PATENT NUMBER: US6044489

CA INDEXING IS CURRENT THROUGH 28 Mar 2000 (20000328/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Mar 2000 (20000328/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 1999

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Nov 1999

>>> Page images are available for patents from 1/1/96. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s L2 and folic acid

3045 FOLIC
486900 ACID
3007 FOLIC ACID
(FOLIC(W)ACID)
L7 1 L2 AND FOLIC ACID

=> display browse

ENTER (L7) OR L#:L7

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L7 ANSWER 1 OF 1 USPATFULL
AN 1999:56501 USPATFULL
TI Method of modulating microcirculation
IN Schneider, Heinz, Cordast, Switzerland
Thurman, Ronald G., Chapel Hill, NC, United States
PA Novartis Nutrition AG, Berne, Switzerland (non-U.S. corporation)
PI US 5902829 19990511

WO 9636327 19961121
 AI US 1998-952806 19980126 (8)
 WO 1996-EP2124 19960517
 19980126 PCT 371 date
 19980126 PCT 102(e) date
 PRAI GB 1995-10037 19950518
 DT Utility
 LN.CNT 634
 INCL INCLM: 514/565.000
 INCLS: 514/045.000
 NCL NCLM: 514/565.000
 NCLS: 514/045.000
 IC [6]
 ICM: A61K031-195
 ICS: A61K031-70
 EXF 514/45; 514/565
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1, kwic

L7 ANSWER 1 OF 1 USPATFULL

SUMM Endogenous **nitric oxide** production can
 also increase blood flow by reducing the number of blood elements
 adhering to the lumen of the vessel. In. . .
 SUMM Examples of vitamins suitable for incorporation into the medicament of
 the invention include Vitamin A, Vitamin D, Vitamin K, **folic**
acid, thiamin, riboflavin, Vitamin B.sub.6, Vitamin B.sub.12,
 niacin, biotin and panthotenic acid in pharmaceutically acceptable
 form.
 SUMM The medicament or formulation is primarily intended for use as a
 dietary
supplement. In such a case, the amount of energy supplied by it
 should not be too excessive, in order not to unnecessarily suppress the
 patients appetite. The **supplement** should conveniently comprise
 energy sources in an amount supplying from 600 to 1500 Kcal/day. The
 contribution of the nitrogen source, . . .

| | | |
|--|------------|-------|
| DETD | . . . diet | 0.10 |
| Zinc | mg/kg diet | 12.00 |
| The vitamin mixture comprises per kg diet: | | |
| A.sup.(1) | 4000.00 | IU |
| D.sup.(2) | 1000.00 | IU |
| E.sup.(3) | 30.00 | IU |
| K.sub.1 | 50.00 | .mu.g |
| Choline | 1000.00 | mg |
| Folic acid | 1.00 | mg |
| Niacin | 20.00 | mg |
| Pantothenate (calcium) | | |
| | 8.00 | mg |
| Riboflavin | 3.00 | mg |
| Thiamin | 4.00 | mg |
| Vitamin B.sub.6 | 6.00 | mg |
| Vitamin B.sub.12 | 50.00 | .mu.g |

.sup.(1) Vitamin A: . . .
 ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:end

=> display his

ENTER (BRIEF) OR FULL:fi8ull

'FI8ULL' IS NOT VALID HERE

If you enter "BRIEF", you will see a short review of your session
 history. If you enter "FULL", you will see a complete review of your

session history.
ENTER (BRIEF) OR FULL:display his

'DISPLAY HIS' IS NOT VALID HERE
If you enter "BRIEF", you will see a short review of your session history. If you enter "FULL", you will see a complete review of your session history.
ENTER (BRIEF) OR FULL:full

ENTER (L1-), L#, OR ?:L1-

(FILE 'HOME' ENTERED AT 17:09:59 ON 03 APR 2000)

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000
L1 30772 SEA SUPPLEMENT
L2 30 SEA L1 AND NITRIC OXIDE PRODUCTION
L3 0 SEA L2 AND SAPONINS
L4 0 SEA L2 AND GENSING
L5 25 SEA L2 AND L(W)ARGININE
L6 1 SEA L2 AND N(W)ACETYL(W)CYSTEINE
DISPLAY BROWSE
L7 1 SEA L2 AND FOLIC ACID
DISPLAY BROWSE

FILE HOME

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Mar 2000 (20000328/PD)
FILE LAST UPDATED: 28 Mar 2000 (20000328/ED)
HIGHEST PATENT NUMBER: US6044489
CA INDEXING IS CURRENT THROUGH 28 Mar 2000 (20000328/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Mar 2000 (20000328/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 1999
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Nov 1999

>>> Page images are available for patents from 1/1/96. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:n

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:n

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 20.13 | 20.28 |

FILE 'CAPLUS' ENTERED AT 17:20:40 ON 03 APR 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 3 Apr 2000 VOL 132 ISS 15
FILE LAST UPDATED: 2 Apr 2000 (20000402/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

=> s nitric oxide production

89184 NITRIC
1023142 OXIDE
278800 PRODUCTION
L8 1039 NITRIC OXIDE PRODUCTION
(NITRIC(W) OXIDE (W) PRODUCTION)

=> s L8 and folic acid

7596 FOLIC
2409206 ACID
7518 FOLIC ACID
(FOLIC(W)ACID)
L9 2 L8 AND FOLIC ACID

=> display browse

ENTER (L9) OR L#:L9

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1-2

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS
AN 1999:819237 CAPLUS
DN 132:35188
TI Enhancement of exercise performance by augmenting endogenous
nitric oxide production or activity
IN Cooke, John P.; Maxwell, Andrew J.
PA Board of Trustees of the Leland Stanford Junior University, USA

```

L1      30772 SEA SUPPLEMENT
L2      30 SEA L1 AND NITRIC OXIDE PRODUCTION
L3      0 SEA L2 AND SAPONINS
L4      0 SEA L2 AND GENSING
L5      25 SEA L2 AND L(W)ARGININE
L6      1 SEA L2 AND N(W)ACETYL(W)CYSTEINE
        DISPLAY BROWSE
L7      1 SEA L2 AND FOLIC ACID
        DISPLAY BROWSE

```

FILE HOME

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Mar 2000 (20000328/PD)

FILE LAST UPDATED: 28 Mar 2000 (20000328/ED)

HIGHEST PATENT NUMBER: US6044489

CA INDEXING IS CURRENT THROUGH 28 Mar 2000 (20000328/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Mar 2000 (20000328/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 1999

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Nov 1999

```

>>> Page images are available for patents from 1/1/96. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<

```

```

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:n

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|--|----------|-----------------|----------|
| PI | WO 9966921 | A1 | 19991229 | WO 1999-US12022 | 19990528 |
| | W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| PRAI | US 1998-103340 | | 19980623 | | |

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1999:231162 CAPLUS

DN 130:251680

TI Enhancement of vascular function by modulation of endogenous
nitric oxide production or activity

IN Cooke, John P.; Dzau, Victor J.; Gibbons, Gary H.

PA The Board of Trustees of the Leland Stanford Junior University, USA

SO U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 336,159, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | US 5891459 | A | 19990406 | US 1995-556035 | 19951109 |
| | US 5428070 | A | 19950627 | US 1993-76312 | 19930611 |
| | US 5852058 | A | 19981222 | US 1996-695792 | 19960812 |
| | WO 9716983 | A1 | 19970515 | WO 1996-US17241 | 19961024 |
| | W: | JP | | | |
| | RW: | AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, | | | |
| SE | EP 871376 | A1 | 19981021 | EP 1996-938656 | 19961024 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | |
| | US 5861168 | A | 19990119 | US 1996-764919 | 19961216 |
| | US 5945452 | A | 19990831 | US 1997-796298 | 19970207 |
| PRAI | US 1993-76312 | | 19930611 | | |
| | US 1994-336159 | | 19941108 | | |
| | US 1995-556035 | | 19951109 | | |
| | US 1996-695792 | | 19960812 | | |
| | WO 1996-US17241 | | 19961024 | | |

DETD . . . amino acids, in combination, or as a precursor to L-arginine, e. g. a monomer or a polypeptide, as a dietary **supplement**. The amino acid(s) is administered as any physiologically acceptable salt, such as the hydrochloride salt, glutamate salt, etc. They can. . .

DETD . . . calcium (250-1000 mg per daily dose). Furthermore, agents known to protect NO from degradation, such as antioxidants (e.g. cysteine or **N-acetyl cysteine** 200-1000 mg/d Vitamin C (250-2000 mg daily dose), (coenzyme Q 25-90 mg daily dose, glutathione 50-250 mg daily dose), Vitamin. . . formulations of R and/or K, or R and/or K-containing peptides. Alternatively, one may include the active agent in a nutritional **supplement**, where other additives may include vitamins, amino acids, or the like, where the subject active agent will be at least. . .

DETD . . . candies, sugar substitutes, soft drinks, and the like. Of particular interest is the incorporation of R and/or K as a **supplement** in a food, such as a health bar, e.g. granola, other grains, fruit bars, such as a date bar, fig. . .

DETD . . . studies, the extent of the thoracic aorta involved by lesions was examined. In hypercholesterolemic rabbits receiving vehicle (n=6) or L-arginine **supplement** (n=6), thoracic aortae (from left subclavian artery to diaphragm) were harvested after ten weeks of treatment, bisected longitudinally, and stained. . .

CLM What is claimed is:

- . . . of the vascular system of a human host by enhancing endothelial NO, said method comprising: administering orally as a dietary **supplement** to said host in accordance with a predetermined regimen a prophylactic dose in an amount sufficient to enhance endogenous endothelial. . .
- . . . of the vascular system of a human host by enhancing endothelial NO, said method comprising: administering orally as a dietary **supplement** to said host in accordance with a predetermined regimen a prophylactic dose in an amount sufficient to enhance endogenous endothelial. . .
- . . . of the vascular system of a human host by enhancing endothelial NO, said method comprising: administering orally as a dietary **supplement** to said host in accordance with a predetermined regimen a prophylactic dose in an amount sufficient to enhance endogenous endothelial. . .

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:end

=> display his

ENTER (BRIEF) OR FULL:full

ENTER (L1-), L#, OR ?:L1-

(FILE 'HOME' ENTERED AT 17:09:59 ON 03 APR 2000)

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000

```

L1      30772 SEA SUPPLEMENT
L2      30 SEA L1 AND NITRIC OXIDE PRODUCTION
L3      0 SEA L2 AND SAPONINS
L4      0 SEA L2 AND GENSING
L5      25 SEA L2 AND L(W)ARGININE
L6      1 SEA L2 AND N(W)ACETYL(W)CYSTEINE
        DISPLAY BROWSE

```

FILE HOME

his file contains CAS Registry Numbers for easy and accurate substance identification.

=> s supplement

L1 30772 SUPPLEMENT

=> s L1 and nitric oxide production

49710 NITRIC
348134 OXIDE
532819 PRODUCTION
207 NITRIC OXIDE PRODUCTION
(NITRIC(W)OXIDE(W) PRODUCTION)

L2 30 L1 AND NITRIC OXIDE PRODUCTION

=> s L2 and saponins

1085 SAPONINS
L3 0 L2 AND SAPONINS

=> s L2 and gensing

2 GENSING
L4 0 L2 AND GENSING

=> s L2 and l(w)arginine

611177 L
19592 ARGININE
3493 L(W)ARGININE
L5 25 L2 AND L(W)ARGININE

=> s L2 and N(w)acetyl(w)cysteine

773027 N
66709 ACETYL
17143 CYSTEINE
398 N(W)ACETYL(W)CYSTEINE
L6 1 L2 AND N(W)ACETYL(W)CYSTEINE

=> display browse

ENTER (L6) OR L#:L6

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L6 ANSWER 1 OF 1 USPATFULL
AN 1999:43208 USPATFULL
TI Enhancement of vascular function by modulation of endogenous
nitric oxide production or activity
IN Cooke, John P., Palo Alto, CA, United States
Dzau, Victor J., Los Altos Hills, CA, United States
Gibbons, Gary H., Palo Alto, CA, United States
PA The Board of Trustees of the Leland Stanford Junior University,
Stanford, CA, United States (U.S. corporation)
PI US 5891459 19990406
AI US 1995-556035 19951109 (8)

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Mar 2000 (20000328/PD)
FILE LAST UPDATED: 28 Mar 2000 (20000328/ED)
HIGHEST PATENT NUMBER: US6044489
CA INDEXING IS CURRENT THROUGH 28 Mar 2000 (20000328/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Mar 2000 (20000328/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 1999
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Nov 1999

>>> Page images are available for patents from 1/1/96. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s L2 and folic acid

3045 FOLIC
486900 ACID
3007 FOLIC ACID
(FOLIC(W)ACID)
L7 1 L2 AND FOLIC ACID

=> display browse

ENTER (L7) OR L#:L7

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L7 ANSWER 1 OF 1 USPATFULL
AN 1999:56501 USPATFULL
TI Method of modulating microcirculation
IN Schneider, Heinz, Cordast, Switzerland
Thurman, Ronald G., Chapel Hill, NC, United States
PA Novartis Nutrition AG, Berne, Switzerland (non-U.S. corporation)
PI US 5902829 19990511
WO 9636327 19961121
AI US 1998-952806 19980126 (8)
WO 1996-EP2124 19960517
19980126 PCT 371 date
19980126 PCT 102(e) date
PRAI GB 1995-10037 19950518
DT Utility
LN.CNT 634
INCL INCLM: 514/565.000
INCLS: 514/045.000
NCL NCLM: 514/565.000
NCLS: 514/045.000
IC [6]
ICM: A61K031-195
ICS: A61K031-70

RLI Continuation-in-part of Ser. No. US 1994-336159, filed on 8 Nov 1994,
now abandoned which is a continuation-in-part of Ser. No. US
1993-76312,
filed on 11 Jun 1993, now patented, Pat. No. US 5428070
DT Utility
LN.CNT 1730
INCL INCLM: 424/439.000
INCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000
NCL NCLM: 424/439.000
NCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000
IC [6]
ICM: A23L001-305
ICS: A61K009-00; A61K031-195
EXF 930/290; 530/358; 426/648; 426/656; 426/657; 514/310; 514/20; 514/557;
514/564; 514/565; 424/439; 424/441
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L6 ANSWER 1 OF 1 USPATFULL
AN 1999:43208 USPATFULL
TI Enhancement of vascular function by modulation of endogenous
nitric oxide production or activity
IN Cooke, John P., Palo Alto, CA, United States
Dzau, Victor J., Los Altos Hills, CA, United States
Gibbons, Gary H., Palo Alto, CA, United States
PA The Board of Trustees of the Leland Stanford Junior University,
Stanford, CA, United States (U.S. corporation)
PI US 5891459 19990406
AI US 1995-556035 19951109 (8)
RLI Continuation-in-part of Ser. No. US 1994-336159, filed on 8 Nov 1994,
now abandoned which is a continuation-in-part of Ser. No. US
1993-76312,
filed on 11 Jun 1993, now patented, Pat. No. US 5428070
DT Utility
LN.CNT 1730
INCL INCLM: 424/439.000
INCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000
NCL NCLM: 424/439.000
NCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000
IC [6]
ICM: A23L001-305
ICS: A61K009-00; A61K031-195
EXF 930/290; 530/358; 426/648; 426/656; 426/657; 514/310; 514/20; 514/557;
514/564; 514/565; 424/439; 424/441
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1, kwic

L6 ANSWER 1 OF 1 USPATFULL
TI Enhancement of vascular function by modulation of endogenous
nitric oxide production or activity
SUMM . . . combination with L-lysine, particularly further supplemented
with GRAS substances which enhance the effectiveness of the active
agents, as a dietary **supplement** will increase NO elaboration
and thereby diminish the effects of atherogenesis. Other techniques to
enhance NO or secondary messenger availability. . .
DRWD FIGS. 2A, 2B, and 2C are nephelometric scans of the effect of
L-arginine
diet **supplement** on platelet reactivity as evidenced by
platelet aggregation initiated by adenosine diphosphate. (See Ex. 2) A)
aggregation of platelets from. . .
DRWD FIG. 3 is a bar diagram comparing the effect of L-arginine diet
supplement on cell binding to aortic endothelium of
hypercholesterolemic animals. (See Ex. 4)